46 related articles for article (PubMed ID: 1651812)
1. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.
Hinds M; Deisseroth K; Mayes J; Altschuler E; Jansen R; Ledley FD; Zwelling LA
Cancer Res; 1991 Sep; 51(17):4729-31. PubMed ID: 1651812
[TBL] [Abstract][Full Text] [Related]
2. Cancer drug resistance: an evolving paradigm.
Holohan C; Van Schaeybroeck S; Longley DB; Johnston PG
Nat Rev Cancer; 2013 Oct; 13(10):714-26. PubMed ID: 24060863
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and insights into drug resistance in cancer.
Zahreddine H; Borden KL
Front Pharmacol; 2013; 4():28. PubMed ID: 23504227
[TBL] [Abstract][Full Text] [Related]
4. Understanding Cancer's Defense against Topoisomerase-Active Drugs: A Comprehensive Review.
Sharma NK; Bahot A; Sekar G; Bansode M; Khunteta K; Sonar PV; Hebale A; Salokhe V; Sinha BK
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398072
[TBL] [Abstract][Full Text] [Related]
5. Naturally mutagenic sequence diversity in a human type II topoisomerase.
Bandak AF; Blower TR; Nitiss KC; Gupta R; Lau AY; Guha R; Nitiss JL; Berger JM
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302064120. PubMed ID: 37406101
[TBL] [Abstract][Full Text] [Related]
6. Predicting Anticancer Drug Resistance Mediated by Mutations.
Lin YF; Liu JJ; Chang YJ; Yu CS; Yi W; Lane HY; Lu CH
Pharmaceuticals (Basel); 2022 Jan; 15(2):. PubMed ID: 35215249
[TBL] [Abstract][Full Text] [Related]
7. Cancer cells undergoing epigenetic transition show short-term resistance and are transformed into cells with medium-term resistance by drug treatment.
Poojan S; Bae SH; Min JW; Lee EY; Song Y; Kim HY; Sim HW; Kang EK; Kim YH; Lee HO; Hong Y; Park WY; Jang H; Hong KM
Exp Mol Med; 2020 Jul; 52(7):1102-1115. PubMed ID: 32661348
[TBL] [Abstract][Full Text] [Related]
8. hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II
Kania EE; Carvajal-Moreno J; Hernandez VA; English A; Papa JL; Shkolnikov N; Ozer HG; Yilmaz AS; Yalowich JC; Elton TS
Mol Pharmacol; 2020 Mar; 97(3):159-170. PubMed ID: 31836624
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy Resistance Explained through Endoplasmic Reticulum Stress-Dependent Signaling.
Bahar E; Kim JY; Yoon H
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30857233
[TBL] [Abstract][Full Text] [Related]
10. Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.
Arnst KE; Banerjee S; Chen H; Deng S; Hwang DJ; Li W; Miller DD
Med Res Rev; 2019 Jul; 39(4):1398-1426. PubMed ID: 30746734
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance in cancer: an overview.
Housman G; Byler S; Heerboth S; Lapinska K; Longacre M; Snyder N; Sarkar S
Cancers (Basel); 2014 Sep; 6(3):1769-92. PubMed ID: 25198391
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms regulating resistance to inhibitors of topoisomerase II.
Ganapathi RN; Ganapathi MK
Front Pharmacol; 2013; 4():89. PubMed ID: 23914174
[TBL] [Abstract][Full Text] [Related]
13. Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha.
Vilain N; Tsai-Pflugfelder M; Benoit A; Gasser SM; Leroy D
Nucleic Acids Res; 2003 Oct; 31(19):5714-22. PubMed ID: 14500835
[TBL] [Abstract][Full Text] [Related]
14. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
Matsumoto Y; Kunishio K; Nagao S
J Neurooncol; 1999; 45(1):37-46. PubMed ID: 10728908
[TBL] [Abstract][Full Text] [Related]
15. Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.
Vassetzky YS; Alghisi GC; Roberts E; Gasser SM
Br J Cancer; 1996 May; 73(10):1201-9. PubMed ID: 8630279
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.
Pommier Y
Cancer Chemother Pharmacol; 1993; 32(2):103-8. PubMed ID: 8387398
[No Abstract] [Full Text] [Related]
17. Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Fisher LM
Br J Cancer; 1993 Mar; 67(3):456-63. PubMed ID: 8382508
[TBL] [Abstract][Full Text] [Related]
18. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
[TBL] [Abstract][Full Text] [Related]
19. Using yeast to study resistance to topoisomerase II-targeting drugs.
Nitiss JL
Cancer Chemother Pharmacol; 1994; 34 Suppl():S6-13. PubMed ID: 8070029
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase expression in cancer cell lines and clinical samples.
Doyle LA
Cancer Chemother Pharmacol; 1994; 34 Suppl():S32-40. PubMed ID: 8070025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
